Feasibility of MR-guided adaptive radiation therapy techniques
The MR-Linac Technical Feasibility Protocol For Development of MR-guided Adaptive RadiationTherapy
This study is testing new ways to use MRI technology during radiation therapy to see if it can make treatment more precise and safer for patients with tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Netherlands Cancer Institute Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Amsterdam) |
| Trial ID | NCT04351204 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility of various new techniques and software for MR-guided adaptive radiation therapy, which allows for real-time monitoring and adjustment of treatment based on changes in tumor and organ positions. By integrating imaging directly at the linear accelerator, the study aims to enhance the precision of radiotherapy and reduce toxicity to surrounding healthy tissues. It involves multiple parallel cohorts of patients treated with radiation therapy on the MR-Linac, with a focus on collecting data on acute toxicity and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are undergoing radiation therapy and meet specific health criteria.
Not a fit: Patients with contraindications for MRI, those who are pregnant, or individuals with severe claustrophobia may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the accuracy and safety of radiotherapy for patients with tumors.
How similar studies have performed: Other studies have shown promise with MR-guided adaptive radiotherapy, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient, age ≥ 18 years, treated with radiation therapy on the MRL. * WHO performance 0-2. * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Contra-indications for an MRI examination. * Patient is pregnant. * Claustrophobia. * Patients \>140 kg and/or a body width \> 60 cm. * Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements or severe psychiatric illness/social situation.
Where this trial is running
Amsterdam
- Netherlands Cancer Institute — Amsterdam, Netherlands (Recruiting)
Study contacts
- Principal investigator: Marlies Nowee, MD, PhD — The Netherlands Cancer Institute
- Study coordinator: Marlies Nowee, MD, PhD
- Email: m.nowee@nki.nl
- Phone: +31 20 512 9111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.